When obesity is present, weight reduction of non-lipedema tissue can be helpful to minimize complications from surgery
"They have done a lot of studies that it lowers the risk of cardiac disease, renal disease and obesity because there's not as much workload on the heart," Lockman said
Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods
Keep reading to find out what you may experience when taking a GLP-1 to lose weight or manage your type 2 diabetes, how common the side effects are, and what steps you can take to help minimize them
I would say the postmenopausal women I treat are not typically super responders, she says
Structured nutrition and lifestyle programmes may be considered for glycaemic benefit and can be adapted for specific cultural indications [83,84,85,86,87]
